{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T22:00:42Z","timestamp":1780524042065,"version":"3.54.1"},"reference-count":23,"publisher":"Tohoku University Medical Press","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tohoku J. Exp. Med."],"published-print":{"date-parts":[[2021]]},"DOI":"10.1620\/tjem.254.49","type":"journal-article","created":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T22:43:45Z","timestamp":1622241825000},"page":"49-55","source":"Crossref","is-referenced-by-count":4,"title":["Phase II Study of the Reuse of Trastuzumab with Docetaxel beyond Progression after First-Line Treatment in Second-Line Treatment for Unresectable, Metastatic Gastric Cancer (T-CORE1203)"],"prefix":"10.1620","volume":"254","author":[{"given":"Masanobu","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"},{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Osaki Citizen Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Otsuka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Miyagi Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Kanbe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Senseki Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatsugu","family":"Ohori","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Japanese Red Cross Ishinomaki Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Shindo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Nakadori General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Surgery, Sendai Open Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Saijo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"},{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Ouchi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Osaki Citizen Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Murakawa","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Miyagi Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Japanese Red Cross Ishinomaki Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadayuki","family":"Kawai","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Osaki Citizen Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Nakadori General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuhiro","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Division of Biostatistics, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Shimodaira","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"},{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology, Yamagata University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikashi","family":"Ishioka","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Tohoku University Hospital"},{"name":"Department of Clinical Oncology, Institute of Development, Aging and Cancer, Tohoku University"},{"name":"Department of Clinical Oncology, Tohoku University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"622","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., Aprile, G., Kulikov, E., Hill, J., Lehle, M., Ruschoff, J., et al.  (2010)  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.  <i>Lancet<\/i>, 376, 687-697.","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"2","doi-asserted-by":"crossref","unstructured":"Boku, N. (2014)  HER2-positive gastric cancer.  <i>Gastric Cancer<\/i>, 17, 1-12.","DOI":"10.1007\/s10120-013-0252-z"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. &amp; Jemal, A. (2018)  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.  <i>CA Cancer J. Clin.<\/i>, 68, 394-424.","DOI":"10.3322\/caac.21492"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Hironaka, S., Ueda, S., Yasui, H., Nishina, T., Tsuda, M., Tsumura, T., Sugimoto, N., Shimodaira, H., Tokunaga, S., Moriwaki, T., Esaki, T., Nagase, M., Fujitani, K., Yamaguchi, K., Ura, T., et al.  (2013)  Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.  <i>J. Clin. Oncol.<\/i>, 31, 4438-4444.","DOI":"10.1200\/JCO.2012.48.5805"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Horita, Y., Nishino, M., Sugimoto, S., Kida, A., Mizukami, A., Yano, M., Arihara, F., Matsuda, K., Matsuda, M. &amp; Sakai, A. (2019)  Phase II clinical trial of second-line weekly paclitaxel plus trastuzumab for patients with HER2-positive metastatic gastric cancer.  <i>Anticancer Drugs<\/i>, 30, 98-104.","DOI":"10.1097\/CAD.0000000000000691"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Ignatov, T., Gorbunow, F., Eggemann, H., Ortmann, O. &amp; Ignatov, A. (2019)  Loss of HER2 after HER2-targeted treatment.  <i>Breast Cancer Res. Treat.<\/i>, 175, 401-408.","DOI":"10.1007\/s10549-019-05173-4"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Inoue, K., Nakagami, K., Mizutani, M., Hozumi, Y., Fujiwara, Y., Masuda, N., Tsukamoto, F., Saito, M., Miura, S., Eguchi, K., Shinkai, T., Ando, M., Watanabe, T., Masuda, N., Ohashi, Y., et al.  (2010)  Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group.  <i>Breast Cancer Res. Treat.<\/i>, 119, 127-136.","DOI":"10.1007\/s10549-009-0498-7"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Lee, J.L., Ryu, M.H., Chang, H.M., Kim, T.W., Yook, J.H., Oh, S.T., Kim, B.S., Kim, M., Chun, Y.J., Lee, J.S. &amp; Kang, Y.K. (2008)  A phase II study of docetaxel as salvage chemotherapy in advanced gastric cancer after failure of fluoropyrimidine and platinum combination chemotherapy.  <i>Cancer Chemother. Pharmacol.<\/i>, 61, 631-637.","DOI":"10.1007\/s00280-007-0516-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Li, Q., Jiang, H., Li, H., Xu, R., Shen, L., Yu, Y., Wang, Y., Cui, Y., Li, W., Yu, S. &amp; Liu, T. (2016)  Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study.  <i>Oncotarget<\/i>, 7, 50656-50665.","DOI":"10.18632\/oncotarget.10456"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Makiyama, A., Sukawa, Y., Kashiwada, T., Kawada, J., Hosokawa, A., Horie, Y., Tsuji, A., Moriwaki, T., Tanioka, H., Shinozaki, K., Uchino, K., Yasui, H., Tsukuda, H., Nishikawa, K., Ishida, H., et al.  (2020)  Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT Study).  <i>J. Clin. Oncol.<\/i>, 38 , 1919-1927.","DOI":"10.1200\/JCO.19.03077"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Mizrak Kaya, D., Harada, K., Shimodaira, Y., Amlashi, F.G., Lin, Q. &amp; Ajani, J.A. (2017)  Advanced gastric adenocarcinoma: optimizing therapy options.  <i>Expert Rev. Clin. Pharmacol.<\/i>, 10, 263-271.","DOI":"10.1080\/17512433.2017.1279969"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Narita, Y., Kadowaki, S., Masuishi, T., Taniguchi, H., Takahari, D., Ura, T., Ando, M., Tajika, M., Niwa, Y., Eto, T., Hara, H., Asayama, M., Yamaguchi, K., Yatabe, Y. &amp; Muro, K. (2017)  Correlation between human epidermal growth factor receptor 2 expression level and efficacy of trastuzumab beyond progression in metastatic gastric cancer.  <i>Oncol. Lett.<\/i>, 14, 2545-2551.","DOI":"10.3892\/ol.2017.6409"},{"key":"13","doi-asserted-by":"crossref","unstructured":"Oh, D.Y. &amp; Bang, Y.J. (2020)  HER2-targeted therapies - a role beyond breast cancer.  <i>Nat. Rev. Clin. Oncol.<\/i>, 17, 33-48.","DOI":"10.1038\/s41571-019-0268-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Palle, J., Tougeron, D., Pozet, A., Soularue, E., Artru, P., Leroy, F., Dubreuil, O., Sarabi, M., Williet, N., Manfredi, S., Martin-Babau, J., Rebischung, C., Abdelghani, M.B., Evesque, L., Dreanic, J., et al.  (2017)  Trastuzumab beyond progression in patients with HER2-positive advanced gastric adenocarcinoma: a multicenter AGEO study.  <i>Oncotarget<\/i>, 8, 101383-101393.","DOI":"10.18632\/oncotarget.20711"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Ponde, N., Brandao, M., El-Hachem, G., Werbrouck, E. &amp; Piccart, M. (2018)  Treatment of advanced HER2-positive breast cancer: 2018 and beyond.  <i>Cancer Treat. Rev.<\/i>, 67, 10-20.","DOI":"10.1016\/j.ctrv.2018.04.016"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Saeki, H., Oki, E., Kashiwada, T., Arigami, T., Makiyama, A., Iwatsuki, M., Narita, Y., Satake, H., Matsuda, Y., Sonoda, H., Shimokawa, M., Maehara, Y. &amp; Kyushu Study Group of Clinical, C. (2018)  Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).  <i>Eur. J. Cancer<\/i>, 105, 41-49.","DOI":"10.1016\/j.ejca.2018.09.024"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Satoh, T., Xu, R.H., Chung, H.C., Sun, G.P., Doi, T., Xu, J.M., Tsuji, A., Omuro, Y., Li, J., Wang, J.W., Miwa, H., Qin, S.K., Chung, I.J., Yeh, K.H., Feng, J.F., et al.  (2014)  Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN\u2014a randomized, phase III study.  <i>J. Clin. Oncol.<\/i>, 32, 2039-2049.","DOI":"10.1200\/JCO.2013.53.6136"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Shitara, K., Bang, Y.J., Iwasa, S., Sugimoto, N., Ryu, M.H., Sakai, D., Chung, H.C., Kawakami, H., Yabusaki, H., Lee, J., Saito, K., Kawaguchi, Y., Kamio, T., Kojima, A., Sugihara, M., et al.  (2020)  Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer.  <i>N. Engl. J. Med.<\/i>, 382, 2419-2430.","DOI":"10.1056\/NEJMoa2004413"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Ter Veer, E., van den Ende, T., Creemers, A., de Waal, L., van Oijen, M.G.H. &amp; van Laarhoven, H.W.M. (2018)  Continuation of trastuzumab beyond progression in HER2-positive advanced esophagogastric cancer: a meta-analysis.  <i>Acta Oncol.<\/i>, 57, 1599-1604.","DOI":"10.1080\/0284186X.2018.1503421"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Thuss-Patience, P.C., Kretzschmar, A., Bichev, D., Deist, T., Hinke, A., Breithaupt, K., Dogan, Y., Gebauer, B., Schumacher, G. &amp; Reichardt, P. (2011)  Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).  <i>Eur. J. Cancer<\/i>, 47, 2306-2314.","DOI":"10.1016\/j.ejca.2011.06.002"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Thuss-Patience, P.C., Shah, M.A., Ohtsu, A., Van Cutsem, E., Ajani, J.A., Castro, H., Mansoor, W., Chung, H.C., Bodoky, G., Shitara, K., Phillips, G.D.L., van der Horst, T., Harle-Yge, M.L., Althaus, B.L. &amp; Kang, Y.K. (2017)  Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2\/3 study.  <i>Lancet Oncol.<\/i>, 18, 640-653.","DOI":"10.1016\/S1470-2045(17)30111-0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Valero, V., Forbes, J., Pegram, M.D., Pienkowski, T., Eiermann, W., von Minckwitz, G., Roche, H., Martin, M., Crown, J., Mackey, J.R., Fumoleau, P., Rolski, J., Mrsic-Krmpotic, Z., Jagiello-Gruszfeld, A., Riva, A., et al.  (2011)  Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens.  <i>J. Clin. Oncol.<\/i>, 29, 149-156.","DOI":"10.1200\/JCO.2010.28.6450"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Wilke, H., Muro, K., Van Cutsem, E., Oh, S.C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.Y., Cunningham, D., Rougier, P., Komatsu, Y., Ajani, J., Emig, M., et al.  (2014)  Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.  <i>Lancet Oncol.<\/i>, 15, 1224-1235.","DOI":"10.1016\/S1470-2045(14)70420-6"}],"container-title":["The Tohoku Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/254\/1\/254_49\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T03:10:03Z","timestamp":1623381003000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/tjem\/254\/1\/254_49\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1620\/tjem.254.49","relation":{},"ISSN":["0040-8727","1349-3329"],"issn-type":[{"value":"0040-8727","type":"print"},{"value":"1349-3329","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}